UltraViolet Devices, Inc. (UVDI) announced its V-MAX UV-C air disinfection technology has achieved 99.99% inactivation of Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) in a single-pass in moving airstream HVAC testing.
The testing was conducted at Innovative Bioanalysis, a BEI-recognized BSL-3 laboratory in California. SARS-CoV-2 is the primary viral strain that causes the COVID-19 infection, which the Centers for Disease Control and Prevention (CDC) has indicated can be spread by both airborne and surface transmission.
In the independent testing, UVDI V-MAX UV-C air disinfection technology eliminated 99.99% of SARS-CoV-2 in a single pass at an airflow rate of 500 feet per minute.
To confirm effectiveness against airborne SARS-CoV-2 in a moving airstream, Innovative Bioanalysis used a HVAC duct test based on a modified ISO 15714 and ASHRAE 185.1 standard. To replicate conditions in a typical HVAC duct, UVDI V-MAX™ 254 nm UV-C lamps were arranged in a parallel configuration.
“This novel testing underlines UVDI’s UV-C technology’s effectiveness against airborne SARS-CoV-2,” stated Dr. Ashish Mathur, Ph.D., UVDI Vice President of Innovation and Technology.
Mathur added, “The study results are further evidence that UVDI provides proven airstream protection – and peace-of-mind – for critical infrastructure globally such as airports, healthcare facilities, schools and government buildings as well as for high-traffic public spaces such as arenas, sports facilities and hospitality sites.”
UVDI’s V-MAX UV-C air disinfection technology works by damaging the DNA of microorganisms, eliminating their ability to reproduce and infect people. UV-C air disinfection product effectiveness against coronavirus is currently supported using established models to estimate the UV-C dose required to inactivate the virus.
The BSL-3 laboratory results also confirm the accuracy of UVDI’s proprietary modelling software, which determines custom product configurations for targeted UV-C effectiveness. The software was used to inform the study’s protocols.
More Info:
https://www.uvdi.com/covid-19/
This article originally appeared at SBT's sister site, Healthcare Purchasing News.
